Clinical Trials Logo
  1. Home
  2. Myeloid Leukemia
  3. NCT00114764

Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)

Myeloid Leukemia Clinical Trial

Official title:
A Multicentre, Double-Blind, Randomised Phase 2 Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)

Clinical Trial Summary

The purpose of this study is to determine if a single dose of pegfilgrastim is able to reduce the time of severe neutropenia in patients receiving induction and consolidation myelosuppressive chemotherapy for de novo acute myeloid leukemia similar to filgrastim.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00114764
Study type Interventional
Source Amgen
Contact
Status Completed
Phase Phase 2
Start date March 2003
Completion date August 2004
View Details
See also
  Status Clinical Trial Phase
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Terminated NCT00543972 - Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia Phase 1
Completed NCT00521664 - A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups Phase 3
Completed NCT05363488 - Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
Completed NCT01380756 - Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia Phase 1
Recruiting NCT05031897 - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant Phase 2
Terminated NCT00126893 - Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia Phase 1
Completed NCT03613727 - Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients Phase 2
Active, not recruiting NCT04714372 - FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia Phase 1
Completed NCT02763475 - NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents Phase 2
Terminated NCT01643603 - Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Phase 1
Completed NCT00497991 - Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia Phase 1
Not yet recruiting NCT05787951 - Frequency and Risk Factors of Acute Myeloid Leukemia
Completed NCT04628338 - IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation Early Phase 1
Completed NCT02719821 - Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation N/A
Active, not recruiting NCT00111345 - Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Phase 2/Phase 3
Recruiting NCT05871008 - Integrated Actionable Aging Assessment for Cancer Patients Pilot N/A
Recruiting NCT03638206 - Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies Phase 1/Phase 2
Recruiting NCT05035706 - Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors Early Phase 1
Terminated NCT00887926 - Study of IMC-EB10 in Participant With Leukemia Phase 1